logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Geron Corporation (GERN) Spikes, Retreats, Spikes Again on Imetelstat Data

By  +Follow December 6, 2013 12:50PM
Share:
Tickers Mentioned:

Shares in biopharmaceutical company Geron Corporation (GERN) took a wild ride on Friday, as the company was up as much as 32 percent in pre-market trading, spiked nearly 18 percent to open trading, swung to a 2.7 percent loss, and then started climbing again. All before 11 am EST.

The wild day came after the company released data after market close on Thursday from a clinical study showing that its bone-marrow drug, imetelstat, displayed statistically significant results among 22 myelofibrosis patients.

Imetelstat Carrying GERN to New Heights

Imetelstat is a treatment for myelofibrosis, a chronic myeloid cancer that affects bone marrow cells. It’s intended to work by inhibiting the activity of telomerase, an enzyme that allows cancer cells to maintain telomere length, which is what gives those cells the capacity for limitless reproduction.

The Mayo Clinic study, which was performed on 22 myelofibrosis patients over six months, achieved partial or complete remission from five of the participants and showed a response to the treatment in 41 percent of people taking the drug.

“Some patients in our clinical trial taking imetelstat obtained dramatic responses and there have been some complete responses which is almost unheard of for drug therapy in this disease,” said Mayo Clinic hematologist Ayalew Tefferi, the study’s lead author, in the statement. “These are early results but they are promising.”

Roller-coaster Day for GERN Stock

The daily movement for Geron proved inconsistent, repeatedly rising sharply only to surrender gains soon after.

After closing at $5.87 a share on Thursday, the stock opened $6.72 a share and rose as high as $6.92 in the first six minutes of trading. It then plunged sharply, falling as low as $5.71 a share just before it started to rebound again at around 11 am. That rebound carried shares to $6.33 a share by just after 12:45 pm, but it was followed by another sharp decline back to $5.87 a share.

Things slowed considerably after 1 pm, but a slow rally to over $6 a share was followed by another decline with shares down over 0.75 percent by 3:45 pm.

GERN On the Rise Since September

The current news on a Mayo Clinic comes almost exactly a month after the company experienced 44.72 percent jump in a single day on new of another Mayo Clinic study returning strong results.

On the whole, it’s been a strong close to 2013 for a stock that showed little life prior to the end of the summer. Shares in Geron have more than quadrupled since September 1, rising over 315 percent since that point. The stock gained less than 1.5 percent over the first 9 months of the year.

Driving the gains are continuing streams of positive news about imetelstat, which investors clearly believe is en route for FDA approval and commercial release as Geron has consistently been losing money since 2009, with annual operating losses between $70 million and $111 million in that time.

Friday’s stops and starts could be a sign that investors and traders believe the three-month run has taken Geron’s value close to long-term resistance.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for GERN
Market News Desk
29 Aug 14 08:21:32
$GERN: GERON CORP Financials http://t.co/nX3GaNMeDn http://t.co/WC5kHXBBc1
AricGoodman
29 Aug 14 08:17:10
$ASTY now back to original cost via $GERN distribution - wish I would've bought more at 2.10 #ripcity
Trader News Daily
29 Aug 14 06:25:35
$GSPN on breakout watch after up 33% yesterday. Related: $APP $ARIA $BRCD $HEMP $GERN $CBIS $CRMBQ $DRIO $DRNE $JRJC $DGLY $HGSE $XXII $ALU
jones_trades
28 Aug 14 21:03:44
Worst Nasdaq trades for me this year $BLDP $ROYL $GERN $HIMX Best trades $GLUU $NEWL $PLUG & $USU
MAISA
28 Aug 14 19:12:26
#StemCell from $GERN to $ASTY - must read! Stem cell industry's 'huge development' in Bay Area http://t.co/rkCDxujLeW
MAISA
28 Aug 14 13:15:30
$GERN overall option implied volatility of 99 is below its 26-week average of 104
Stock Updates
28 Aug 14 10:21:32
$GERN: Geron to Assume Sponsorship of Myelofibrosis IST and IND http://t.co/nXAZN41011 http://t.co/tWW39EfJDC
BLAZING VOLTz
28 Aug 14 10:05:21
i went small cap bio shopping today -- added: $CLRX $BLRX $OPXA $IMMU $GERN $KBIO and $ABIO -- sold all my $SGOC and $CPRX -
work1411
27 Aug 14 13:45:33
$GERN $ASTY - http://t.co/frEBRdxDXe
Biotex
27 Aug 14 12:16:28
contemplating picking up $GERN at these levels..
Thomas Lynch
27 Aug 14 12:07:09
$ASTY,former gern ip starts spinal trials http://t.co/xoZ6VjsWLP $cur $gern
il falso guaritore
27 Aug 14 11:38:45
RT @AndyBiotech: $PFE opens Ph2 Single Agent Study of PF-04449913 (Hedgehog pathway SMO inhibitor) In #Myelofibrosis http://t.co/zSZxSeI1xM…
Trader News Daily
27 Aug 14 11:31:37
http://t.co/PeRPkYu8Uk ranked #1 with over 75% alert gains this week. Related: $AVNR $HALB $HYSR $XSNX $ZQK $CIM $BLUU $DRNE $MACK $GERN
Colin White
27 Aug 14 09:00:45
RT @AndyBiotech: $PFE opens Ph2 Single Agent Study of PF-04449913 (Hedgehog pathway SMO inhibitor) In #Myelofibrosis http://t.co/zSZxSeI1xM…
DM Oncology
27 Aug 14 09:00:41
RT @AndyBiotech: $PFE opens Ph2 Single Agent Study of PF-04449913 (Hedgehog pathway SMO inhibitor) In #Myelofibrosis http://t.co/zSZxSeI1xM…
JonnyFinlay
27 Aug 14 08:42:15
RT @AndyBiotech: $PFE opens Ph2 Single Agent Study of PF-04449913 (Hedgehog pathway SMO inhibitor) In #Myelofibrosis http://t.co/zSZxSeI1xM…
Mathew Pletcher
27 Aug 14 08:36:09
RT @AndyBiotech: $PFE opens Ph2 Single Agent Study of PF-04449913 (Hedgehog pathway SMO inhibitor) In #Myelofibrosis http://t.co/zSZxSeI1xM…
Business Updates
27 Aug 14 08:21:29
$GERN: Geron to Assume Sponsorship of Myelofibrosis IST and IND http://t.co/ez7eCgMcOV http://t.co/z1R7SXkbdp
Marc Hav
27 Aug 14 08:20:19
$GERN on the move ! http://t.co/0drhgqIeNE
Market Masta
27 Aug 14 08:20:06
$GERN & $ONVO 'today is gonna be a good day' - Ice Cube
Ronald J. Perez, PhD
27 Aug 14 08:13:01
RT @AndyBiotech: $PFE opens Ph2 Single Agent Study of PF-04449913 (Hedgehog pathway SMO inhibitor) In #Myelofibrosis http://t.co/zSZxSeI1xM…
Andy Biotech
27 Aug 14 08:11:29
$PFE opens Ph2 Single Agent Study of PF-04449913 (Hedgehog pathway SMO inhibitor) In #Myelofibrosis http://t.co/zSZxSeI1xM $INCY $GERN $CRIS
Taylor Anderson
27 Aug 14 07:31:34
@adamfeuerstein $ASTY OPC1 CIRM grant less than 50% of what $GERN gave up when they stopped progam
Jacob Plieth
27 Aug 14 07:25:58
@sharkbiotech Asterias? Bizarre story. Subsidiary of $BTX, formed to develop $GERN stem cell assets. Convoluted setup...
sububoston
27 Aug 14 07:18:02
@sharkbiotech $gern
WKRB News
27 Aug 14 06:26:15
Zacks Reaffirms Neutral Rating for Geron $GERN http://t.co/pq6hqo7YJd
Marc Hav FX
27 Aug 14 06:13:01
Geron Corporation $GERN (Updated 27AUG2014) http://t.co/MEmmftPI19
Marc Hav
27 Aug 14 06:13:00
Geron Corporation $GERN (Updated 27AUG2014) http://t.co/zJI8H8ovv6
Drew
27 Aug 14 00:01:50
“@StockCats: $GERN long signal http://t.co/jHQiqKNoab” RT->A fav takeout a target. Long for years & will continue.
Kevin Kennedy
26 Aug 14 20:22:43
RT @StockCats: $GERN long signal http://t.co/0ZXcqpxU8n
Business News Now
26 Aug 14 20:21:25
$GERN: Geron Corporation Reports Second Quarter 2014 Financial Results http://t.co/zlGeaUCEIw http://t.co/7i3lmFb7Gv
Market Masta
26 Aug 14 20:05:03
RT @StockCats: $GERN long signal http://t.co/0ZXcqpxU8n
00Matt
26 Aug 14 19:46:12
“@StockCats: $GERN long signal http://t.co/hOlErPUKDT” like this one a lot with 2.20 area support as risk/stop
Scott Thomas
26 Aug 14 19:45:36
RT @StockCats: $GERN long signal http://t.co/0ZXcqpxU8n
S Manian
26 Aug 14 19:28:55
“@StockCats: $GERN long signal http://t.co/HyzoX6th5j” // 3's #jamot IMO
S Manian
26 Aug 14 19:26:48
RT @MarketMasta: $GERN volume
StockCats
26 Aug 14 19:25:45
$GERN long signal http://t.co/0ZXcqpxU8n
deb
26 Aug 14 17:18:45
@MarketMasta next time! ps good entry on $GERN, good r:r there
Market Masta
26 Aug 14 10:57:03
going to be aggressive here and grab some $GERN @ 2.32
US Banking News
26 Aug 14 10:29:05
Geron’s Neutral Rating Reaffirmed at Zacks $GERN http://t.co/0bC7L6yDoZ
Business Headlines
26 Aug 14 10:21:28
$GERN: Geron Corporation Reports Second Quarter 2014 Financial Results http://t.co/RQjyf8BYjA http://t.co/z86uYlDsDH
InterCooler
26 Aug 14 10:06:42
Zacks Reiterates “Neutral” Rating for Geron $GERN http://t.co/mMFWYaAyTs
Analyst Ratings
26 Aug 14 10:05:22
Geron's neutral rating reiterated at Zacks. $2.50 PT. http://t.co/xCu9LrP4Iy $GERN #GERN
US Consumer News
26 Aug 14 10:05:09
Geron's neutral rating reiterated at Zacks. $2.50 PT. http://t.co/gxd8mkzLXG $GERN #GERN
Ticker Report
26 Aug 14 09:59:18
Geron’s Neutral Rating Reiterated at Zacks $GERN http://t.co/G8oGsRmkhN
Market Masta
26 Aug 14 07:01:07
$GERN volume
Market Masta
26 Aug 14 05:53:11
Watchlist Tuesday 8/26: $ASTC $MXWL $WRES $GERN $JNUG
Market Masta
25 Aug 14 15:44:30
RT @Marc_Hav: Updated charts: $HOV $ARWR $AXP $BAC $BBRY $CHK $CLVS $CNP $CNQ $GERN $GPOR $KKD $KERX $L $CRNT http://t.co/zOR1VaGf15
Steph Seguin
25 Aug 14 15:30:46
RT @Marc_Hav: Geron Corporation $GERN (Updated 25AUG2014) http://t.co/GMQGf18apE
Steph Seguin
25 Aug 14 15:29:56
RT @Marc_Hav: Updated charts: $HOV $ARWR $AXP $BAC $BBRY $CHK $CLVS $CNP $CNQ $GERN $GPOR $KKD $KERX $L $CRNT http://t.co/zOR1VaGf15
				
				
By  +Follow December 6, 2013 12:50PM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.